Manejo clínico de la neoplasia trofoblástica gestacionalpresentación de un caso
- Solé, A. 1
- Pascual, Y. 1
- Rodríguez, A.B. 1
- Méndez, D.C. 1
- Muñoz, A.M. 1
- González, D. 2
- Pérez, E. 2
- 1 Hospital Río Hortega. Valladolid. Servicio de Obstetricia y Ginecología
- 2 Hospital Río Hortega. Valladolid. Servicio de Anatomía Patológica
ISSN: 1139-8264
Ano de publicación: 2021
Volume: 24
Número: 2
Páxinas: 63-66
Tipo: Artigo
Outras publicacións en: Revista española de investigaciones quirúrgicas
Resumo
Gestational trophoblastic disease is a rare entity that is caused by an abnormal proliferation of the placenta. It encompasses a diverse spectrum of histological entities, which carry various clinical implications. Some of them are benign (partial mole and complete mole, placentomegaly, placental site nodule) and others of a malignant nature, which are known as Gestational Trophoblastic Neoplasia (GTN) and have a high potential for metastasization. Are part of the GTN: invasive mole, trophoblastic tumor of the placental site, trophoblastic tumor epithelioid and gestational choriocarcinoma. The most common is that NTG debuts after the appearance of a molar gestation, but it also may occur after another type of obstetric event such as a term gestation, or an ectopic gestation. It is therefore of vital importance to carry out a correct follow-up after evacuating a molar gestation, monitoring the serum values of BhcG and suspecting a persistent trophoblastic disease in the event that we will later describe. The main therapeutic tool for NTG is the use of chemotherapy, although surgery can also be chosen in certain cases. It will be necessary to assess individually according to histology, prognostic score and future genetic desires of the patient. Fortunately, the survival and cure rate of NTG with proper treatment and follow-up is very high.